Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Lenvatinib + Pembrolizumab for Head and Neck Cancer
Recruiting1 awardPhase 2
Cleveland, Ohio
This trial is testing if lenvatinib combined with pembrolizumab or lenvatinib alone is better for patients with head and neck cancer that hasn't responded to other treatments. Lenvatinib stops cancer growth, and pembrolizumab boosts the immune system to fight cancer. Lenvatinib has shown better curative effects when combined with other treatments compared to its use as a single agent.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service